- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02052037
Egg Ingestion in Adults With Type 2 Diabetes
Egg Ingestion in Adults With Type 2 Diabetes: Effects on Glycemic Control, Anthropometry, Diet Quality and Cardiometabolic Status A Randomized, Controlled, Crossover Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Hypothesis Inclusion of eggs in the diets of individuals with Type 2 diabetes mellitus will improve glycemic control, anthropometric measures and overall diet quality.
Restriction of dietary cholesterol, and thus the avoidance or restriction of egg intake, is routinely recommended to patients at increased risk for CVD, including those with diabetes. However, the relative importance of dietary cholesterol to serum lipids and the role of egg ingestion in cardiovascular risk are increasingly suspect. Further, the exclusion of eggs from the diet may lead to increased consumption of high-glycemic carbohydrate foods of particular potential harm to individuals with diabetes. The examination of how food-specific recommendations translate into effects on other food choices and overall diet quality, and in turn health effects, is a neglected area of research.
Eggs provide a complete profile of amino acids and an array of micronutrients, and are low in total fat. Although epidemiological and clinical studies largely suggest a lack of association between egg intake and harmful effects, the evidence is somewhat more ambiguous with regard to glycemic control for diabetes, or the risk for CVD among individuals with diabetes. Our own prior work shows no adverse effects of egg ingestion in healthy adults, hyperlipidemic adults, or adults with established coronary artery disease. As a satiating and protein-rich food, eggs have potential to foster calorie and weight control, and to reduce the dietary glycemic load, offering potential advantages in Type 2 diabetes.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Connecticut
-
Derby, Connecticut, United States, 06418
- Yale-Griffin Prevention Research Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- males age greater than 35 years;
- post-menopausal females not currently on hormone replacement therapy;
- non-smokers;
- clinical diagnosis of Type 2 diabetes mellitus for at least 1 year but no more than 5 years;
- 6.5% ≤ HbA1c ≤8.0% (5) BMI between 25 and 40 kg/m².
Exclusion Criteria:
- failure to meet inclusion criteria;
- anticipated inability to complete study protocol for any reason;
- current eating disorder;
- use of antihyperglycemic, lipid-lowering or antihypertensive medications unless stable on medication for at least 3 months;
- use of glucocorticoids, antineoplastic agents, psychoactive agents, or nutraceuticals;
- regular use of fiber supplements;
- restricted diets (i.e., vegetarian, vegan, gluten free);
- known allergy to eggs.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Egg inclusion
Participants will meet with a registered dietitian and receive instructions for including 2 eggs per day (10 to 14 eggs/week) in their meal plan, while preserving an isocaloric condition relative to the egg exclusion phase.
The study dietitian will provide individualized guidance to participants on how to make room for eggs in their diet, while giving them latitude in determining how to adjust for the extra calories from the eggs, to better approximate real-world conditions.
|
Participants will meet with a registered dietitian and receive instructions for including 2 eggs per day (10 to 14 eggs/week)in their meal plan, while preserving an isocaloric condition relative to the egg exclusion phase.
The study dietitian will provide individualized guidance to participants on how to make room for eggs in their diet, while giving them latitude in determining how to adjust for the extra calories from the eggs, to better approximate real-world conditions.
Treatment phase will last for 12 weeks.
|
Experimental: Egg exclusion
Participants will meet with the dietitian and receive relevant meal planning guidance and instructions to avoid eggs and specific egg-containing products. During both intervention phases, study participants will be advised to eat to their usual state of fullness, and dietary monitoring and weighing will be conducted to ensure that an isocaloric condition is maintained. |
Participants will meet with the dietitian and receive relevant meal planning guidance and instructions to avoid eggs and specific egg-containing products. During both intervention phases, study participants will be advised to eat to their usual state of fullness, and dietary monitoring and weighing will be conducted to ensure that an isocaloric condition is maintained. Treatment phase will last for 12 weeks. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Glycemic Index
Time Frame: 12-weeks
|
Glycated hemoglobin A1c (HbA1c) will be used to measure the average plasma glucose concentration.
|
12-weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Fasting glucose and insulin
Time Frame: 12-weeks
|
Glucose and insulin will be measured at each time point.
Participants will be asked to fast at least 8 hours before glucose and insulin measurement.
Homeostasis Model Assessment (HOMA-IR) values will be calculated from fasting serum glucose and serum insulin levels using HOMA calculator version 2.2.1 to gauge the degree of insulin resistance.
|
12-weeks
|
Body Composition
Time Frame: 12- weeks
|
Body composition will be measured using bioelectrical impedance analysis, which uses the resistance of electrical flow through the body to estimate body fat.
The Tanita SC-240 Body Composition Analyzer will be used to measure body composition.
The SC-240 Body Composition Analyzer measures weight and calculates body fat% and total body water% in addition to BMI.
|
12- weeks
|
Body Weight
Time Frame: 12- weeks
|
Body weight will be measured during each visit.
It will be measured to the nearest 0.5 pound using a balance-type medical scale.
Subjects will be measured in the morning (fasting), unclothed with the exception of undergarments.
|
12- weeks
|
Waist Circumference
Time Frame: 12-weeks
|
Waist circumference will be measured using the U.S. government standard protocol.
It will be measured around the narrowest point between ribs and hips when viewed from the front after exhaling.
|
12-weeks
|
Diet Quality
Time Frame: Baseline, 6-weeks, 12-weeks
|
To help the study team track any variation in dietary pattern over the course of the study, all participants will be asked at two time points to provide information on the foods and beverages that they consumed during a 3-day period.
For each 3-day period, participants will complete three 24-hour recalls using a web-based Automated Self-Administered 24-Hour Recall (ASA24) (available from the National Cancer Institute at http://riskfactor.cancer.gov/tools/instruments/asa24/)
which will guide them through the process of completing the recall data.
Diet quality will be assessed using the Alternative Healthy Eating Index (AHEI).
3-day food period data will be collected at baseline, 6 weeks and 12 weeks.
|
Baseline, 6-weeks, 12-weeks
|
Physical Activity
Time Frame: 12-weeks
|
Physical activity will be determined by the Seven-Day Physical Activity Recall [PAR].
The PAR is one of the most widely used physical activity assessments in exercise science and epidemiological research.
The popularity of this measure stems largely from its versatility and relative ease of use for research applications.
The PAR provides detail regarding the duration, intensity, and volume (energy expenditure) of physical activity and can therefore be used for a variety of applications.
Because it utilizes a one-week time frame, the data from the PAR is often considered representative of typical activity patterns.
While it requires considerable cognitive effort by the participants, the interviewer administered version can be completed in a reasonable amount of time (~20 minutes).
Variation in physical activity level will be controlled in our multivariable regression models.
|
12-weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: David L. Katz, MPH,MD, Yale-Griffin Prevention Research Center
- Principal Investigator: Valentine Y. Njike, MPH,MD, Yale-Griffin Prevention Research Center
Publications and helpful links
General Publications
- Njike VY, Annam R, Costales VC, Yarandi N, Katz DL. Which foods are displaced in the diets of adults with type 2 diabetes with the inclusion of eggs in their diets? A randomized, controlled, crossover trial. BMJ Open Diabetes Res Care. 2017 Jul 13;5(1):e000411. doi: 10.1136/bmjdrc-2017-000411. eCollection 2017.
- Njike VY, Ayettey RG, Rajebi H, Treu JA, Katz DL. Egg ingestion in adults with type 2 diabetes: effects on glycemic control, anthropometry, and diet quality-a randomized, controlled, crossover trial. BMJ Open Diabetes Res Care. 2016 Dec 22;4(1):e000281. doi: 10.1136/bmjdrc-2016-000281. eCollection 2016.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2013-05 (Other Identifier: Assistance Publique Hôpitaux de Marseille)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 2 Diabetes
-
Antonio Di MauroCompletedType-2 DiabetesItaly
-
DiaMedica Therapeutics IncCompletedDiabetes Type 2Netherlands
-
RenJi HospitalUnknownType 2 Diabetes.China
-
University of Erlangen-Nürnberg Medical SchoolCompletedType 2-diabetesGermany
-
Chengdu Brilliant Pharmaceutical Co., Ltd.Not yet recruitingType 2 Diabetes Mellitus
-
Nanjing First Hospital, Nanjing Medical UniversityRecruitingType 2 Diabetes MellitusChina
-
Xiangya Hospital of Central South UniversityRecruitingType 2 Diabetes MellitusChina
-
University of Alabama at BirminghamCompletedType 2 Diabetes MellitusUnited States
-
Imperial College LondonAstraZeneca; Huma; North West London Collaboration of CCGs (NWL CCGs); Imperial...CompletedType 2 Diabetes MellitusUnited Kingdom
-
Universiti Sains MalaysiaCompleted
Clinical Trials on Egg inclusion
-
Hugh A Sampson, MDNational Institute of Allergy and Infectious Diseases (NIAID); Consortium of...CompletedFood AllergyUnited States
-
University of North Carolina, Chapel HillUniversity of ArkansasCompletedFood HypersensitivityUnited States
-
Universidad de AntioquiaInstituto Colombiano para el Desarrollo de la Ciencia y la Tecnología (COLCIENCIAS)Completed
-
University of California, DavisCompletedObesity | OverweightUnited States
-
Griffin HospitalAmerican Egg BoardCompletedCoronary Artery DiseaseUnited States
-
University of ConnecticutAmerican Egg BoardRecruitingInflammatory Response | LipoproteinsUnited States
-
Pennington Biomedical Research CenterEgg Nutrition CenterCompleted
-
University of IdahoUniversity of Nevada, Las Vegas; University of New MexicoRecruitingDepression | Stress | AnxietyUnited States
-
Centre Hospitalier Universitaire DijonCompleted
-
Washington University School of MedicineUniversity of California, Davis; RTI International; Universidad San Francisco... and other collaboratorsCompleted